Protein Engineering Market- Growth, Trends, and Forecasts (2020 - 2025)

The Protein Engineering Market is segmented by Product Type (Insulin, Monoclonal Antibodies, Coagulation Factors (Blood Factors + Tissue Plasminogen), Vaccines, Growth Factors (Hormones + Cytokine), and Other Product Types), Technology (Irrational Protein Design and Rational Protein Design), End User (Pharmaceutical and Biotechnology Companies, Academic Institutions, and Contract Research Organizations (CROs)), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).

Protein Engineering Market Snapshot

Study Period:

2020-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

15.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The propelling factors for the growth of the global protein engineering market include the increasing prevalence of protein-deficient diseases, the increase in adoption of protein drugs over non-protein drugs, increased demand for alternatives to chemical processes, and rising government funding for protein engineering.

Protein-energy malnutrition (PEM) is increasing in the rural areas of emerging economies. It refers to a group of disorders that include marasmus, kwashiorkor, and intermediate states of marasmus-kwashiorkor. Therefore, the prevalence of kwashiorkor varies across geographies. It is rare in the United States. However, some of the affected regions include Southeast Asia, Central America, Congo, Puerto Rico, Jamaica, and South Africa. Thus, the increasing prevalence of protein-deficient diseases is driving the demand for the overall market.

There is a rising number of government initiatives, such as funding R&D for protein engineering and awareness programs, which influenced the healthcare industry. Thus, the government is proactively investing in many of the research studies. For instance, Protein Technologies Ltd (PTL) received funding from the UK government’s Technology Strategy Board (now Innovate UK), for its innovative research in protein engineering. Hence, the increasing number of government initiatives for the efficient protein engineering research helps in driving the overall growth of the market.

Protein engineering also holds an immense opportunity in the agrochemical industry, as engineering in proteins may lead to the generation of enzymes with improved function, that may increase the crop yield or facilitate the biofuel production. It is also likely to play an important role as a tool, to attain increased crop yield needed to meet future demands.

Scope of the Report

As per the scope of the report, protein engineering is the manipulation of the structures of proteins to produce the desired properties, or the synthesis of proteins with particular structures. It is a process by which novel proteins with desired properties are developed, and it has grown enormously since the past three decades. In the past few years, protein engineers have successfully generated a wide range of proteins tailored to specific health, industry, medicine, research, and biotechnology applications.

By Product Type
Insulin
Monoclonal Antibodies
Coagulation Factors (Blood Factors + Tissue Plasminogen)
Vaccines
Growth Factors (Hormones + Cytokine)
Other Product Types
By Technology
Irrational Protein Design
Rational Protein Design
By End User
Pharmaceutical and Biotechnology Companies
Academic Institutions
Contract Research Organizations (CROs)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Monoclonal Antibodies by Protein Type is Expected to be Largest Contributor in the Market over the Forecast Period

Monoclonal antibodies are anticipated to hold the largest market share over the forecast period, owing to their high adoption for numerous therapies, such as cancer and autoimmune diseases. The increasing prevalence of cancer and other autoimmune diseases has significantly increased the use of monoclonal bodies for the treatment of diseases. They also have tremendous applications in the fields of therapeutics, diagnostics, and targeted drug delivery systems, for infectious diseases caused by viruses, bacteria, protozoa, metabolic and hormonal disorders. Hence, recombinant deoxyribonucleic acid technology, through genetic engineering, has successfully led to the possibility of reconstruction of monoclonal antibodies, in turn, fueling the growth of the segment.

To understand key trends, Download Sample Report

Asia-Pacific Witnessed the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period

Asia-Pacific is expected to witness the fastest CAGR during the forecast period, owing to the growing presence of contract research organizations, rising healthcare IT spending, and unprecedented evolution of the healthcare infrastructure and standards across the region. Growing demand for personalized medicine and strong R&D investments in proteomics-based drug discovery projects are also supplementing the growth of the protein engineering market.

To understand geography trends, Download Sample Report.

Competitive Landscape

The protein engineering market players are highly focused on strategies, such as mergers and acquisitions, new product development initiatives, and geographical expansion. As the cost of R&D is high and requires high-end infrastructure, most of the pharmaceutical and biotechnology companies are moving toward CROs. Most of the players in the CRO industry are joining forces, in order to create a market position.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Protein-deficient Diseases

      2. 4.2.2 Increased Demand for Alternatives to Chemical Processes

      3. 4.2.3 Increase in Adoption of Protein Drugs over Non-protein Drugs

      4. 4.2.4 Rising Government Funding for Protein Engineering

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Experts to Strategize the Process

      2. 4.3.2 High Costs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Insulin

      2. 5.1.2 Monoclonal Antibodies

      3. 5.1.3 Coagulation Factors (Blood Factors + Tissue Plasminogen)

      4. 5.1.4 Vaccines

      5. 5.1.5 Growth Factors (Hormones + Cytokine)

      6. 5.1.6 Other Product Types

    2. 5.2 By Technology

      1. 5.2.1 Irrational Protein Design

      2. 5.2.2 Rational Protein Design

    3. 5.3 By End User

      1. 5.3.1 Pharmaceutical and Biotechnology Companies

      2. 5.3.2 Academic Institutions

      3. 5.3.3 Contract Research Organizations (CROs)

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Agilent Technologies Inc.

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Bruker Corporation

      4. 6.1.4 Bio-Rad Laboratories Inc.

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 Merck KGaA

      7. 6.1.7 Novo Nordisk AS

      8. 6.1.8 PerkinElmer Inc.

      9. 6.1.9 Thermo Fisher Scientific Inc.

      10. 6.1.10 Waters Corporation

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports